Zacks Small Cap Research

IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February 11th press release in preparation for presentation of data at the Transplantation & Cellular Therapy (TCT) Meetings in Hawaii last week. Data for patients enrolled in the trial were updated from early August 2024 to January 17th, 2025. All of the acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months. All of the AML patients achieved one year of progression free survival (PFS) and overall survival (OS). Since our last update, IN8bio has participated in multiple investor and scientific conferences, including Biotech Showcase, Noble’s Emerging Growth Conference, the American Society of Hematology Annual Meeting and the TCT meetings.